Loading...
XNASPRTA
Market cap824mUSD
Dec 23, Last price  
15.33USD
1D
0.72%
1Q
-30.38%
Jan 2017
-68.84%
IPO
125.44%
Name

Prothena Corporation PLC

Chart & Performance

D1W1MN
XNAS:PRTA chart
P/E
—
P/S
9.03
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.11%
Rev. gr., 5y
148.98%
Revenues
91m
+69.50%
1,243,000507,0002,658,000676,00050,854,0001,607,0001,055,00027,519,000955,000814,000853,000200,577,00053,905,00091,370,000
Net income
-147m
L+25.72%
-12,482,000-29,670,000-41,411,000-40,996,000-7,150,000-80,612,000-160,108,000-153,237,000-155,645,000-77,677,000-111,144,00066,975,000-116,949,000-147,028,000
CFO
-134m
L+23.05%
-9,083,000-19,697,000-42,072,000-32,098,000-683,000-62,455,000-117,269,000-131,183,000-28,276,000-52,969,000-80,362,00092,605,000-108,821,000-133,906,000
Earnings
Feb 10, 2025

Profile

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
URL
https://www.prothena.com/
IPO date
Dec 21, 2012
Employees
127
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
91,370
69.50%
53,905
-73.13%
200,577
23,414.30%
Cost of revenue
502,977
192,203
210,886
Unusual Expense (Income)
NOPBT
(411,607)
(138,298)
(10,309)
NOPBT Margin
Operating Taxes
(13,452)
(8,656)
4,946
Tax Rate
NOPAT
(398,155)
(129,642)
(15,255)
Net income
(147,028)
25.72%
(116,949)
-274.62%
66,975
-160.26%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,583
223,616
190,332
BB yield
-1.22%
-7.84%
-7.95%
Debt
Debt current
2,228
6,473
5,940
Long-term debt
22,556
6,473
18,712
Deferred revenue
67,405
85,293
102,933
Other long-term liabilities
553
553
Net debt
(594,046)
(699,672)
(555,794)
Cash flow
Cash from operating activities
(133,906)
(108,821)
92,605
CAPEX
(2,810)
(464)
(575)
Cash from investing activities
(2,773)
(464)
(575)
Cash from financing activities
45,103
241,457
190,332
FCF
(406,145)
(123,515)
(9,028)
Balance
Cash
618,830
710,406
579,094
Long term investments
2,212
1,352
Excess cash
614,262
709,923
570,417
Stockholders' equity
(979,494)
(832,482)
(715,588)
Invested Capital
1,621,213
1,546,843
1,297,442
ROIC
ROCE
EV
Common stock shares outstanding
53,216
47,369
48,464
Price
36.34
-39.68%
60.25
21.96%
49.40
311.32%
Market cap
1,933,869
-32.24%
2,853,982
19.21%
2,394,122
399.42%
EV
1,339,823
2,154,310
1,838,328
EBITDA
(410,679)
(137,554)
(3,506)
EV/EBITDA
Interest
6,696
Interest/NOPBT